Loading organizations...
Based in Oslo, Norway, Circio is a biotechnology company that develops novel circular RNA vector expression technology for advanced gene and cell therapies. The company's proprietary circVec platform is designed to significantly enhance protein expression, offering up to 15-fold higher and 70-fold more durable expression compared to conventional mRNA systems. Publicly listed on Euronext Oslo with over 102 million shares issued, the firm operates a platform-based business model focused on licensing its technology to external partners. Circio conducts research and development at the Karolinska Institute in Sweden and collaborates with Agenus Inc., which licenses the STIMULON QS-21 adjuvant for the company's legacy TG01 cancer vaccine. The organization was originally founded as Targovax prior to its 2016 public listing, and its current operations are led by circRNA co-discoverers Erik Digman Wiklund and Thomas Birkballe Hansen.
Circio has raised $5.8M across 2 funding rounds.
Circio has raised $5.8M in total across 2 funding rounds.
Circio has raised $5.8M across 2 funding rounds. Most recently, it raised $3.6M Grant / Other Equity in June 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 6, 2013 | $3.6M Grant | — | Algot Invest, Radium Hospital Research Foundation, Research Council OF Norway | Announced |
| Feb 1, 2012 | $2.2M Series A | — | Hans Ivar Robinson, Radium Hospital Research Foundation, RO Invest | Announced |
Circio has raised $5.8M in total across 2 funding rounds.
Circio's investors include Algot Invest, Radium Hospital Research Foundation, Research Council of Norway, Hans Ivar Robinson, Ro Invest.
